Additional high-throughput screening of 1280 pharmacologically active compounds using a human CRC cell line expressing a S100A4 promoter-driven luciferase reporter gene construct showed that niclosamide, an anthelminthic agent widely used to treat helminthic infection, was the strongest potential transcription inhibitor of CTNNB1/TCF interaction that impaired S100A4 expression and S100A4-induced metastasis [171]. The gene discussed is S100A4; the disease is colorectal carcinoma.